Sionna Therapeutics, Inc. (SION)
$4.38-6.61%Close
BUYCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $198M
- Beta
- 1.32
- P/E (TTM)
- -2.01
- Short % float
- 14.27%
- Days to cover
- 2.3
- SI change
- -4.3%
- 1W
- -7.79%
- 1M
- -46.97%
- vs SPY 1W
- -7.65%
- vs SPY 1M
- -49.48%
Industry peers
FMP comparable companies · ranked by market cap
- ABCLBUYAbCellera Biologics Inc.$3.9BCRISISQ -6$12.83-0.24%
- VERASELLVera Therapeutics, Inc.$2.2BCRISISQ 20$30.25-3.35%
- CLDXSELLCelldex Therapeutics, Inc.$2.0BCRISISQ 5$30.43-4.01%
- ZYMESELLZymeworks Inc.$2.0BBEARQ 12$26.53-1.03%
- IMNMSELLImmunome, Inc.$1.8BCRISISQ 17$19.09-8.20%
- BHVNSELLBiohaven Ltd.$1.8BCRISISQ 16$11.88-3.30%
- XERSBUYXeris Biopharma Holdings, Inc.$1.7BBULLQ -1$10.11-2.49%
- MAZEBUYMaze Therapeutics, Inc.$1.5BRECOVERYQ 36$26.25-3.75%
- JANXBUYJanux Therapeutics, Inc.$1.1BRECOVERYQ 11$17.92-5.34%
- ARDXSELLArdelyx, Inc.$805MBEARQ 0$3.26-3.41%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on SION?
- LOPJLB’s latest quantitative signal on Sionna Therapeutics, Inc. (SION) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is SION in?
- Sionna Therapeutics, Inc. (SION) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Sionna Therapeutics, Inc. (SION) do?
- Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-10…